biostudies-literatureYu PNIA NIH HHSNHLBI NIH HHSFDA HHSNational Institute for Health Research (NIHR)U.S. Food and Drug AdministrationNINDS NIH HHSNational Institutes of HealthNational Institute of Biomedical Imaging and BioengineeringNational Institute on AgingScience Foundation Arizona808-18https://www.ebi.ac.uk/biostudies/studies/S-EPMC4201941biostudies-literatureUnknown35(4)The objective of this study was to evaluate the effect of computational algorithm, measurement variability, and cut point on hippocampal volume (HCV)-based patient selection for clinical trials in mild cognitive impairment (MCI). We used normal control and amnestic MCI subjects from the Alzheimer's Disease Neuroimaging Initiative 1 (ADNI-1) as normative reference and screening cohorts. We evaluated the enrichment performance of 4 widely used hippocampal segmentation algorithms (FreeSurfer, Hippocampus Multi-Atlas Propagation and Segmentation (HMAPS), Learning Embeddings Atlas Propagation (LEAP), and NeuroQuant) in terms of 2-year changes in Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and Clinical Dementia Rating Sum of Boxes (CDNeurobiology of agingOperationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size.PMC4201941U01 AG010483R01AG034062R01 AG011378U01-HL096917U19 AG010483U01 HL096917NF-SI-0513-10134R01 AG041851U01FD003865U01 AG032438U01 AG10483P30 AG010129R01-AG041851NF-SI-0508-10123P50 AG005131R01-AG037551R01 AG037551U01-AG032438K02 NS067427R01-AG011378U01-AG024904R01 AG034062U01 FD003865U01 AG024904K01 AG030514SRG 0335-08Stephenson DBrewer JFox NCSchwarz AJYu PHill DLJack CRCoalition Against Major Diseases and the Alzheimer's Disease Neuroimaging InitiativeCole PEWolz RSun JfalseOperationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size.The objective of this study was to evaluate the effect of computational algorithm, measurement variability, and cut point on hippocampal volume (HCV)-based patient selection for clinical trials in mild cognitive impairment (MCI). We used normal control and amnestic MCI subjects from the Alzheimer's Disease Neuroimaging Initiative 1 (ADNI-1) as normative reference and screening cohorts. We evaluated the enrichment performance of 4 widely used hippocampal segmentation algorithms (FreeSurfer, Hippocampus Multi-Atlas Propagation and Segmentation (HMAPS), Learning Embeddings Atlas Propagation (LEAP), and NeuroQuant) in terms of 2-year changes in Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and Clinical Dementia Rating Sum of Boxes (CD2014-01-01T00:00:00Z2014 Apr2025-04-22T21:59:59.534Z2019-03-27T01:37:57ZS-EPMC42019412421100810.1016/j.neurobiolaging.2013.09.039